ERBB2 and breast cancer: One of those occurrences is the molecular subtype switching that is repeatedly observed in metastatic breast cancers where malignant cells lose the expression or functionality of the estrogen and progesterone receptors (ER, PR) and gain expression of HER2 [99,100,101].